Boulder, CO – According to filings with the U.S. Securities and Exchange Commission, MBio Diagnostics is raising $11,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Chris Myatt played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MBio Diagnostics

MBio Diagnostics is the innovator of the proprietary point-of-care LightDeck platform that delivers highly sensitive, lab-quality results in minutes. We are developing a portfolio of in vitro diagnostic tests for medical settings where reliable, fast results are vital in making time-critical decisions. We also have a diverse set of collaborative projects with government, academic and commercial partners.

To learn more about MBio Diagnostics, visit http://mbiodx.com/

Contact:
Chris Myatt, Chief Executive Officer
303-952-2905
chris.myatt@mbiodx.com
https://www.linkedin.com/in/chris-myatt-6511862/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved